Il Comitato I Malati Invisibili è presente e attivo nel territorio nazionale da aprile 2014.

(+39) 000 0000 000

info@imalatiinvisibili.it
Via Monte Suello 1/12a – 16129 Genova (IT)

Salva

Articoli recenti

CF 95173870106

info@imalatiinvisibili.it

Via Monte Suello 1/12A

16129 Genova (IT)

Malattie rare – Disabilità dello sviluppo neurologico causata da varianti in TCF20

Genet Med. 2019 Sep;21(9):2036-2042

Author information

  1. GeneDx, Gaithersburg, MD, USA. etorti@genedx.com.
  2. Département de génétique, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
  3. Genetics of Learning Disability Service, Hunter New England Health, Waratah, NSW, Australia.
  4. Australia School of Women’s’ and Children’ Health, University of New South Wales, Sydney, NSW, Australia.
  5. GeneDx, Gaithersburg, MD, USA.
  6. Département de génétique et embryologie médicale, Hôpital Trousseau, Assistance publique-Hôpitaux de Paris, Paris, France.
  7. Centre de Référence malformations et maladies congénitales du cervelet, Paris, France.
  8. Sorbonne Universités, GRC ConCer-LD, Hôpital Armand Trousseau, Paris, France.
  9. Department of Medicine, Division of Genetics, the University of Tennessee Graduate School of Medicine, University Genetics, Knoxville, TN, USA.
  10. Department of Pediatrics, Division of Genetics and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA.
  11. Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
  12. Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  13. Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
  14. HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
  15. Greenwood Genetic Center, Greenwood, SC, USA.
  16. Centre de Référence Déficiences Intellectuelles de Causes Rares, Paris, France.
  17. Sorbonne Université, GRC “Déficience Intellectuelle et Autisme”, Paris, France.
  18. CHU Nantes, Service de Génétique Médicale, Nantes, France.
  19. l’Institut du Thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.
  20. St. Vincent Hospital and Health Services, Indianapolis, IN, USA.
  21. University Genetics, University of Tennessee Medical Center, Knoxville, TN, USA.
  22. University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, USA.
  23. Division of Genetics and Metabolism, Nicklaus Children’s Hospital, Miami, FL, USA.
  24. Connecticut Children’s Medical Center, Farmington, CT, USA.
  25. School of Medicine, University of Connecticut, Farmington, CT, USA.
  26. Department of Medical Genetics, Lyon University Hospitals, Lyon, France.
  27. Lyon Neuroscience Research Centre, CNRS UMR5292, INSERM U1028, Claude Bernard Lyon I University, Lyon, France.
  28. Spectrum Health Medical Genetics, Grand Rapids, MI, USA.
  29. Albany Medical Center, Albany, NY, USA.
  30. Sorbonne Universités, Institut du Cerveau et de la Moelle épinière, ICM, Inserm U1127, CNRS UMR 7225, Paris, France.
  31. Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
  32. Department of Pediatrics, New York University School of Medicine, New York, NY, USA.
  33. Riley Hospital for Children, Indianapolis, IN, USA.
  34. Department of Pediatric Neurology, Women Mother and Children Hospital, Lyon University Hospitals, Lyon, France.
  35. Service de neuropédiatrie, Hôpital Trousseau, Assistance publique-Hôpitaux de Paris, Paris, France.
  36. Unité Fonctionnelle de génétique clinique, Hôpital Armand Trousseau, Assistance publique-Hôpitaux de Paris, Centre de Référence des anomalies du développement et syndromes malformatifs, Paris, France.
  37. GeneDx, Gaithersburg, MD, USA. jjuusola@genedx.com.

Abstract

SCOPO

Per definire le caratteristiche cliniche dei pazienti con varianti in TCF20, sono stati 27 pazienti, 26 dei quali sono stati identificati tramite il sequenziamento dell’esoma. I dati clinici dettagliati sono stati poi confrontati con 17 pazienti precedentemente refertati.

METODI

I pazienti sono stati confermati avere le varianti in esame attraverso laboratori di test molecolari che eseguivano il sequenziamento dell’esoma (e altri test) con conferma di biomarcatori ortogonali; tramite collaborazione con i loro clinici di riferimento che hanno fornito dettagliate informazioni cliniche.

RISULTATI

La coorte di 27 pazienti aveva tutte le nuove varianti e aveva un’età compresa tra 2 e 68 anni.

Per continuare a leggere la news in lingua originale:

Fonte: “Variants in TCF20 in neurodevelopmental disability: description of 27 new patients and review of literature.”, PubMed.gov

Tratto da: https://www.ncbi.nlm.nih.gov/pubmed/30739909